TNFRSF10A and nasopharyngeal carcinoma: Since in C17-PDX cells expression of Trail-R1 was absent and expression of TRAIL-R2 low, and in a recent analysis on the expression of TRAIL receptors in tumors of 174 patients with NPC, TRAIL-R1 and -R2 were detected only in 29.9% and 36.2% of tumors, respectively [28], we asked whether incubation of NPC cells with IFNβ would increase expression of TRAIL receptors.